NCT04461340 is a Phase 2 clinical trial of Sirolimus in COVID 19, sponsored by Alexandria University.

Who is sponsoring NCT04461340?

NCT04461340 is sponsored by Alexandria University.

What drugs are being tested in NCT04461340?

Interventions in NCT04461340: Sirolimus.

Is NCT04461340 still recruiting?

NCT04461340 is currently status unknown. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT04461340

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Sirolimus in COVID-19 Infection

Status unknown Phase 2 Last updated 9 September 2020

What this trial tests

Phase 2 trial testing Sirolimus in COVID 19 in 40 participants. Status unknown.

Timeline

15 August 2020

Primary endpoint
30 October 2020

30 November 2020

Quick facts

Lead sponsor	Alexandria University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	15 August 2020
Primary completion	30 October 2020
Estimated completion	30 November 2020
Sites	1 location across Egypt

Drugs / interventions tested

Sirolimus (sirolimus) — full drug profile →

Conditions studied

COVID 19 — all drugs for COVID 19 →

Sponsor

Alexandria University

Who can join

18 and older, any sex, with COVID 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is planned to illustrate the efficacy and safety of sirolimus as an adjuvant agent to the standard treatment protocol against COVID-19 infection

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Modulation of Macrophage Immunometabolism: A New Approach to Fight Infections.
Gauthier T, Chen W. · · 2022 · cited 99× · PMID 35154105 · DOI 10.3389/fimmu.2022.780839
The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19.
Basile MS, Cavalli E, McCubrey J, Hernández-Bello J, et al · · 2022 · cited 81× · PMID 34763066 · DOI 10.1016/j.drudis.2021.11.002
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6
Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2.
Shi G, Chiramel AI, Li T, Lai KK, et al · · 2022 · cited 44× · PMID 36264642 · DOI 10.1172/jci160766
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.
Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M. · · 2021 · cited 39× · PMID 33665645 · DOI 10.1016/s2666-7568(20)30068-4
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
Pereira GJDS, Leão AHFF, Erustes AG, Morais IBM, et al · · 2021 · cited 36× · PMID 33920748 · DOI 10.3390/ijms22084067

Verify or expand the search:

Other trials of Sirolimus

Trials testing the same drug.

NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
NCT06876142 — Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · Phase 1, PHASE2 · suspended
NCT07052929 — Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators · Phase 1, PHASE2 · recruiting
NCT04370795 — Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-bas · Phase 1, PHASE2 · withdrawn
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other recruiting trials for COVID 19

Currently open trials in the same condition.

NCT06871293 — Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19 · NA · recruiting
NCT06599658 — COVID-19 Booster and IIV Schedule in Immunocompromised Hosts · Phase 2 · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04522076 — Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acq · active not recruiting
NCT06702540 — Bio-reconfigurable Electronic Platform for Multiplex Detection of Viral Respiratory Pathogens · active not recruiting

Other Alexandria University trials

Trials by the same sponsor.

NCT07517861 — Integrated Mental Health Nursing Program: Effects on Stigma, Cognitive Flexibility, and Clinical Readiness · NA · recruiting
NCT07476482 — The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delive · NA · enrolling by invitation
NCT07476209 — Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia · NA · recruiting
NCT07503626 — Optimization of Orthodontic Bracket Placement by Using Two Different Protocols of Digitally Aided Bonding · NA · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04461340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexandria University
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing